Precision ALS

Combining applied clinical research with cutting-edge data science to realise the power of AI towards new drug development in Motor Neuron Disease.

Unlocking the power of data for precision medicine

Precision ALS is an Irish led research programme involving researchers from across Europe along with industry partners and charities focused on harnessing artificial intelligence to analyse large amounts of data to treat Amyotrophic Lateral Sclerosis (ALS), otherwise known as Motor Neurone Disease.


Neurodegenerative diseases are debilitating incurable conditions that cause decline in movement, thinking and behaviour. They occur in later life, and include common conditions such as Alzheimers Disease, Parkinsons Disease, Secondary Progressive Multiple Sclerosis and rarer conditions such as ALS and frontotemperol dementia (FTD). Over 16% of the European population has a neurodegenerative conditions.


In the coming 20 years, the number of patients with progressive neurodegenerative conditions will rapidly increase as the population age increases with improved ageing care.  The development of future treatments will require a precision-medicine based approach however overcoming the factors that have limited the success of translational medicine will require novel solutions.

Partnership to fight chronic disease

Precision ALS is creating a pan-European Patient Data Platform so that research sites across Europe can work together towards a common goal of finding a treatment for ALS. Precision ALS is a unique programme that brings together Clinicians, Computer Scientists, Information Engineers, Technologists, and Data Scientists.  The researchers are collaborating with a number of companies to generate a sustainable precision medicine-based approach towards new drug development that will have many benefits including better clinical outcomes for patients and reducing the economic cost of these diseases.

Email: [email protected]